KROS MEXC RealStocks
Own real KROS shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-18 17:15:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Keros Therapeutics, Inc. (KROS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $12.01, with a market capitalization of $196.83M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.98 to $22.55. This page covers its latest market performance, valuation, price trends and company information.
$196.83M | |
$11.23 | |
$12.35 | |
$11.11 | |
$11.31 | |
264.94K | |
187.54K | |
-- | |
$22.55 | |
$8.98 | |
-- | |
2026-09-30 |
Keros Therapeutics, Inc. (KROS) is currently trading at $12.01 as of 2026-11-18 17:13:00, up 6.19% ($0.70) from the previous close of $11.31
During today's regular trading session, KROS has traded between $11.11 and $12.35, with a trading volume of 264.94K shares. The current price is near the upper end of today's range.
Over the past seven days, Keros Therapeutics, Inc. (KROS) moved from $9.17 to $12.01, representing a gain of 30.97% ($2.84).
The stock traded between $8.98 and $12.35 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 293.52 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 22.3%
KROS is currently trading at $12.01, placing it 22.3% of the way from its 52-week low of $8.98 to its 52-week high of $22.55. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 92 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Keros Therapeutics, Inc. (KROS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to KROS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between KROS shares and USD.
KROS Shares to USD
1.00 KROS shares = 12.01 USD
Calculations are estimates based on the latest available price and are for reference only.